# Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Study · id `cardio:ct-nct06468202` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06468202](<https://clinicaltrials.gov/study/NCT06468202>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06468202

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10742 participants.

## Technical summary

Registry record NCT06468202. Randomized; quadruple masking; primary purpose prevention. Start 2024-10-18 (actual); primary completion 2029-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 10742 participants (planned count; ClinicalTrials.gov record NCT06468202, source copy `cardio:ctgov-nct06468202-2026-10-27`, retrieved 2026-10-31)
- Started: 2024-10-18 (actual) (ClinicalTrials.gov record NCT06468202, source copy `cardio:ctgov-nct06468202-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2029-01-01 (anticipated) (ClinicalTrials.gov record NCT06468202, source copy `cardio:ctgov-nct06468202-2026-10-27`, retrieved 2026-10-31)
- Completion: 2030-02-01 (anticipated) (ClinicalTrials.gov record NCT06468202, source copy `cardio:ctgov-nct06468202-2026-10-27`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT06468202, source copy `cardio:ctgov-nct06468202-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06468202-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
- Acronym: ASPIRIN
- Condition: Hypertensive Disorders of Pregnancy
- Condition: Preeclampsia
- Condition: Gestational Hypertension
- Intervention (Drug): Aspirin 81 mg
- Intervention (Drug): Aspirin 162 mg
- Lead sponsor: Ohio State University
- Lead sponsor class: OTHER
- Collaborator: Patient-Centered Outcomes Research Institute
- Collaborator class: OTHER
- Collaborator: Northwestern University
- Collaborator class: OTHER
- Collaborator: Preeclampsia Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Ohio State University (`cardio:org-ohio-state-university`)
- Registry lists this organization as a collaborator: Patient-Centered Outcomes Research Institute (`cardio:org-patient-centered-outcomes-research-institute`)
- Registry lists this organization as a collaborator: Northwestern University (`cardio:org-northwestern-university`)

## Provenance

Content hash: dbaabca0c9e6b010e292a6bddfa1a6661c76512c9e301a5af7f77b12bc877bcf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
